New data on sparsentan, the FDA‑approved endothelin‑angiotensin blocker for focal segmental glomerulosclerosis (FSGS), is prompting clinicians to reassess the place of older therapies such as corticosteroids and renin‑angiotensin system (RAS) inhibitors.
How sparsentan fits into current FSGS treatment
For decades physicians have observed roughly one‑third of FSGS patients respond well to corticosteroids, while a similar share achieve notable proteinuria reduction with calcineurin inhibitors. ACE inhibitors and ARBs have been used almost universally as add‑on agents because they modestly lower protein excretion and protect kidney function.
Sparsentan targets the combined biology of endothelin and angiotensin pathways, which together aggravate glomerular damage. By blocking both signals, the drug may replace RAS inhibitors in many cases. “It could become a reasonable first‑line option to lower proteinuria,” said Dr. Trachtman, adding that immunosuppressive agents would still be needed for patients whose disease does not respond adequately.
Related: User Blocked After Policy Violation
The recommendation does not imply that steroids or calcineurin inhibitors are obsolete; their mechanisms address immune‑mediated injury, a distinct component of FSGS that sparsentan does not target.
Practical considerations for switching patients
When asked how to advise patients already on older drugs, Dr. Trachtman noted the decision requires careful weighing of risks and benefits. Tolerance for lingering proteinuria differs by underlying disease. For example, individuals with membranous nephropathy often accept higher protein levels without a dire outlook, while emerging data from IgA nephropathy suggest any proteinuria may be harmful.
Future research will clarify the exact proteinuria thresholds needed to alter the disease’s natural course and will define how best to combine traditional agents with sparsentan once those benchmarks are known. In the meantime, many clinicians will likely substitute an ACE inhibitor or ARB with sparsentan, since patients are already accustomed to that mechanism and have not shown a decline in kidney function.
Monitoring protocols are unlikely to change dramatically, although the dual endothelin receptor blockade calls for continued vigilance to detect any adverse effects during the transition.
Related: Users Report Website Access Blocks
Sparsentan’s entry changes the therapeutic picture, illustrating a shift toward more targeted pharmacology in nephrology. Historically, treatment relied heavily on broad immunosuppression and general blood‑pressure control. The new drug’s mechanism reflects a growing understanding of the molecular pathways that drive kidney injury, suggesting that future advances may continue to refine treatment to the specific disease processes at work.
Implications for future research
Upcoming discussions will turn to the DUPLEX trial, which examines sparsentan’s efficacy in a controlled setting. The trial’s design, enrollment criteria, and chosen endpoints will offer insight into how the drug performs across diverse patient populations and how it might be integrated with existing therapies.
Dr. Trachtman anticipates that the results will inform guidelines on proteinuria targets and combination regimens, potentially establishing sparsentan as a cornerstone of FSGS management. Until then, physicians are urged to weigh the benefits of replacing ACE inhibitors or ARBs against each patient’s individual risk profile and to maintain careful observation during therapy changes.
